An Act to Clarify the Requirements for Accessing Nonformulary Drugs and Drugs Used to Treat Serious Mental Illness
Summary
LD 1100 amends Maine insurance law to clarify when health carriers must approve access to prescription drugs that are not on a plan’s formulary, with a particular focus on drugs used to assess or treat serious mental illness. The bill requires a carrier to approve prior authorization for formulary medications prescribed for serious mental illness, and if a formulary drug is unavailable because of a shortage and no equivalent formulary alternative exists, the carrier must approve an equivalent nonformulary drug for as long as the shortage lasts. It also defines “serious mental illness” by reference to a mental disorder causing serious functional impairment, and authorizes the superintendent to adopt routine technical rules to implement the provision.
The bill also amends the existing access-to-clinically-appropriate-drugs statute to reinforce that enrollees, their designees, or prescribing providers may request coverage of a drug not otherwise covered by the plan. If the carrier approves such a request, the drug must be treated as an essential health benefit for cost-sharing and actuarial-value purposes. The carrier must decide and notify the requester within 72 hours, or within 24 hours in exigent circumstances, and approved coverage must continue for the duration of the prescription or exigency, including refills where applicable.
Impact
The bill would modify Title 24-A of the Maine Revised Statutes governing health insurance carriers and prescription drug coverage. It strengthens access requirements for nonformulary medications, especially for people being treated for serious mental illness, and creates a clearer obligation for carriers to cover equivalent nonformulary drugs during formulary shortages. It also preserves and clarifies the existing process for requesting clinically appropriate drugs not otherwise covered, including timing requirements, expedited review, and treatment of approved drugs as essential health benefits.
Sentiment
Based on the bill text and the absence of recorded committee testimony or votes in the provided materials, the overall sentiment appears supportive of improving access to needed medications and reducing barriers created by formulary restrictions or drug shortages. The measure is framed as a clarification and access-protection bill rather than a major policy shift, suggesting a generally consumer- and patient-oriented intent. No recorded opposition or divided vote is available in the provided context.
Contention
The main policy tension in LD 1100 is between ensuring timely access to medically necessary drugs and preserving carrier control over formularies, utilization management, and cost containment. Potential points of contention include the requirement to approve nonformulary equivalents during shortages, the speed of carrier decision-making, and the mandate to treat approved non-covered drugs as essential health benefits for cost-sharing and actuarial-value purposes. The bill text does not show any specific stakeholder objections, but insurers could be expected to focus on administrative burden and cost exposure, while patient advocates and prescribers would likely support the expanded access.